Tuesday, February 27, 2024
HomeFunding Helsinki-based Resistomap Secures €2 Million in Seed Funding

[Funding alert] Helsinki-based Resistomap Secures €2 Million in Seed Funding

Helsinki-based Resistomap secures €2 million in seed funding. In order to create a biosecurity intelligence platform specifically designed to handle the intricate and difficult problems of environmental antimicrobial resistance (AMR).

Helsinki-based Resistomap secures €2 million in seed funding. In order to create a biosecurity intelligence platform specifically designed to handle the intricate and difficult problems of environmental antimicrobial resistance (AMR).

The U.S.-based co-investor Gaingels took part in the funding round, which was headed by the European venture capital firm Ananda Impact Venture. Additional support came from an R&D grant from Business Finland.

Read also – UK-based Accenture Acquire 6point6

This announcement solidifies Resistomap’s standing as a pioneer in the industry and comes after years of devoted study into environmental AMR. Notably, the financing is provided at a critical time when biosecurity procedures and wastewater-based epidemiology (WBE) projects are receiving more attention.

Windi Muziasari, CEO and Founder of Resistomap, said: “Citing the Dutch philosopher Desiderius Erasmus, “prevention is better than cure,” which resonates well with our mission at Resistomap to mitigate the global spread of antibiotic resistance and preserve the efficacy of antibiotics. To achieve this, we need an intelligent platform that leverages our environmental monitoring data. Our vision goes beyond AMR to build a comprehensive biosecurity platform that addresses a diverse array of disease-causing pathogens, encompassing both those already identified and those that remain undiscovered.”

Antimicrobial resistance (AMR), sometimes known as the “silent pandemic,” is a serious worldwide health concern. Antibiotic resistance results from bacterial adaptation and medication resistance to antimicrobial agents.

Read also – SUPPLYZ Rebrands as RESONIKS and Secures Investment from Kvanted

As a result, infections that were once under control are now harder to treat, which raises mortality rates and drives up medical expenses. Despite pledges to lead the way in developing novel antibiotics and guarantee their equitable distribution worldwide, proactive infection control is still glaringly underemphasized.

An extensive and useful environmental surveillance data set is lacking, which makes it more difficult to take measures to slow the development of this silent pandemic.

Zoe Peden, Partner at Ananda Impact Ventures, commented: “For too long, antibiotic resistance has loomed as an approaching storm cloud, and so we take great pride in standing alongside Resistomap in its efforts to break this storm while pushing environmental health to the forefront of decision-making worldwide. This investment seamlessly aligns with our commitment to address multi-faceted, systemic global challenges. By fostering collaboration, innovation and robustness in the environmental health sector, we will make great strides toward a healthier future fighting antibiotic resistance.”

Tuomas Harju, Senior Adviser for the Health & Wellbeing Industry at Business Finland, added: “Curbing the spread of antibiotic resistance is critical and there is a great need for innovative solutions to accomplish this. We are proud to support Resistomap on their mission to make continuous monitoring of antibiotic resistance a reality globally.”

About Resistomap

Resistomap, which was established in 2018 and is run by CEO Windi Muziasari, has painstakingly created one of the largest environmental AMR databases to date in collaboration with its clients.

This large dataset provides valuable insights into the complex field of antibiotic resistance and will serve as the basis for Resistomap’s future development of its services into an intelligence platform.

Read also – Chasse sur Rhône-based Recyc’ELIT Raises €3.2M in Funding

This platform will incorporate personalised advice for limiting the spread of AMR, in-depth genetic data, advanced prediction models on the disease’s progress, and early-warning systems.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular